rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Santhosh Palani

Director

Company insider

Files Form 4 as: Director, Acrivon Therapeutics; Director, Pyxis Oncology.

In numbers

Trades disclosed
11
Buys
0
Sells
0
Bought
$0
Sold
$0
Companies
2
Companies where not an officer
2
First trade
4 Mar 2024
Last trade
17 Jun 2026
Last filed
22 Jun 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
ACRV Acrivon TherapeuticsDirector · Biotechnology · last 17 Jun 20260 buys · 0 sells
PYXS Pyxis OncologyDirector · Biotechnology · last 24 Mar 20260 buys · 0 sells

Activity over time

Not enough dated trades to draw.

Every trade

TradedCompanyWhatAmount
17 Jun 2026filed 22 Jun 2026ACRV Acrivon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—20,275 at $0.00filing
17 Jun 2026filed 22 Jun 2026ACRV Acrivon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—20,275 at $0.00filing
18 May 2026filed 20 May 2026ACRV Acrivon TherapeuticsBiotechnologySEC FORM 4 Code A—9,366 at $0.00filing
18 May 2026filed 20 May 2026ACRV Acrivon TherapeuticsBiotechnologySEC FORM 4 Code A—9,366 at $0.00filing
24 Mar 2026filed 25 Mar 2026PYXS Pyxis Oncologyoption or derivative · BiotechnologySEC FORM 4 Code A—45,867 at $0.00filing
24 Mar 2026filed 25 Mar 2026PYXS Pyxis Oncologyoption or derivative · BiotechnologySEC FORM 4 Code A—45,867 at $0.00filing
13 Jun 2025filed 17 Jun 2025ACRV Acrivon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—20,275 at $0.00filing
31 Mar 2025filed 2 Apr 2025PYXS Pyxis Oncologyoption or derivative · BiotechnologySEC FORM 4 Code A$36K36,979 at $0.98filing
7 Jun 2024filed 7 Jun 2024PYXS Pyxis OncologyBiotechnologySEC FORM 4 Code A—6,000 at $0.00filing
12 Mar 2024filed 13 Mar 2024PYXS Pyxis Oncologyoption or derivative · BiotechnologySEC FORM 4 Code A—69,760 at $0.00filing
4 Mar 2024filed 6 Mar 2024ACRV Acrivon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—32,500 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

No trade we could place in a sector.

Related people

GordonMD Global Investments LP10% owner · 10% owner at Pyxis Oncology, filing Form 4 there in the last year
Mary MillerChief Legal Officer · Chief Legal Officer at Acrivon Therapeutics, filing Form 4 there in the last year
Thomas CivikCEO & Chairman of the Board · CEO & Chairman of the Board at Pyxis Oncology, filing Form 4 there in the last year
Michaela LevinChief Business Officer · Chief Business Officer at Acrivon Therapeutics, filing Form 4 there in the last year
Peter Blume-JensenPresident and CEO · President and CEO at Acrivon Therapeutics, filing Form 4 there in the last year